Thrivent Financial for Lutherans’s Ultragenyx Pharmaceutical RARE Stock Holding History

Thrivent Financial for Lutherans’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26,261	Closed	-$550K	–	2669
2026 Q1	$550K	Buy	+26,261	New	+$591K	﹤0.01%	2178
2023 Q3	–	Sell	-37,950	Closed	-$1.75M	–	2486
2023 Q2	$1.75M	Sell	37,950 -1,861	-5%	-$86.3K	﹤0.01%	1429
2023 Q1	$1.6M	Buy	39,811 +2,825	+8%	+$121K	﹤0.01%	1452
2022 Q4	$1.71M	Sell	36,986 -11,483	-24%	-$452K	﹤0.01%	1355
2022 Q3	$2.01M	Buy	48,469 +11,483	+31%	+$590K	0.01%	1214
2022 Q2	$2.21M	Buy	+36,986	New	+$2.28M	0.01%	1181
2022 Q1	–	Sell	-20,757	Closed	-$1.75M	–	2537
2021 Q4	$1.75M	Buy	+20,757	New	+$1.69M	﹤0.01%	1484
2018 Q2	–	Sell	-8,801	Closed	-$449K	–	2028
2018 Q1	$449K	Buy	+8,801	New	+$443K	﹤0.01%	1695

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Thrivent Financial for Lutherans's RARE Position: Q2 2026 in Review

Thrivent Financial for Lutherans sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 26,261 shares — an estimated $550K sold.

Thrivent Financial for Lutherans first reported a position in RARE in Q1 2018 and held it in 8 quarters. The position peaked at $2.21M in Q2 2022. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Thrivent Financial for Lutherans reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Thrivent Financial for Lutherans sold 26,261 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $550K.
Thrivent Financial for Lutherans first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and held it in 8 quarters.
Thrivent Financial for Lutherans's Ultragenyx Pharmaceutical position peaked at $2.21M in Q2 2022.
310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.